AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/07/26	EUR 0.6450	+0.78%	753,420
14/07/26	EUR 0.6400	-7.65%	734,954
13/07/26	EUR 0.6930	-5.46%	421,843
10/07/26	EUR 0.7330	-2.27%	144,000
09/07/26	EUR 0.7500	+1.35%	245,638

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 01:55:00 16/07/26 am AEST			After hours 03:52:32 am
0.6450 ^EUR	+0.78%		0.6460	+0.16%

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI

Market Cap	51.21M 58.57M 47.24M 43.43M 82.28M 5.64B 83.69M 564M 221M 2.75B 220M 215M 9.49B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	51.21M 58.57M 47.24M 43.43M 82.28M 5.64B 83.69M 564M 221M 2.75B 220M 215M 9.49B	EV / Sales 2026 *	42.7x	EV / Sales 2027 *	39.4x
Free-Float	72.29%	Yield 2026 *	-	Yield 2027 *	-

01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI
29/06	AB Science completes Step 3 of a Phase 1 study
18/06	AB Science Secures US Patent for Prostate Cancer Therapy	MT
18/06	AB Science Secures New U.S. Patent for Masitinib
18/06	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
10/06	AB Science presents new data on Masitinib
18/05	AB Science S.A. announced that it has received $2.989368 million in funding	CI
14/05	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/05	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
29/04	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
29/04	AB Science announces successful capital increase

11/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU
01/07	AB Science announces the successful completion of a EUR 2.3 million private placement	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	GL
29/06	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML	AQ

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

13/07	Bourse : Go West pour Stellantis, Apple se fâche contre OpenAI, Akzo courtisé
13/07	Wall Street ne chômera pas le 14 juillet
11/07	AB Science rationalise son portefeuille et se recentre sur deux molécules
11/07	AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques
08/07	Stéphane Ledermann prend les rênes d'AB Science en tant que PDG

1 day	+0.78%
1 week	-12.84%
Current month	-27.12%
1 month	-27.36%
3 months	-47.04%
6 months	-54.26%
Current year	-58.01%

1 week	0.61	0.75
1 month	0.61	0.94
Current year	0.61	1.61
1 year	0.61	1.73
3 years	0.61	4.46
5 years	0.61	16.68
10 years	0.61	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/05	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.78%	-12.84%	-50.91%	-83.52%	58.6M
MERCK & CO., INC.	+2.21%	-1.97%	+51.50%	+16.99%	298B
MERCK KGAA	+0.43%	+0.68%	+27.36%	-5.85%	69.4B
HALOZYME THERAPEUTICS, INC.	+1.28%	-5.60%	+34.05%	+88.40%	8.9B
KYOWA KIRIN CO., LTD.	-0.79%	-2.76%	+6.65%	-0.47%	8.6B
SK BIOPHARMACEUTICALS CO., LTD.	+4.83%	-7.89%	-18.20%	+2.22%	3.93B
BETTA PHARMACEUTICALS CO., LTD.	-3.81%	+3.61%	+15.50%	+32.17%	4.34B
YUHAN CORPORATION	+4.20%	-1.14%	-37.61%	+22.65%	3.34B
SUPERNUS PHARMACEUTICALS, INC.	+1.70%	-5.87%	+41.69%	+61.33%	2.71B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+4.15%	+5.19%	+15.20%	-15.61%	2.19B
Average	+1.50%	-2.28%	+8.52%	+11.83%	40.18B
Weighted average by Cap.	+1.83%	-5.08%	+43.90%	+14.43%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.02M 1.93M 132M 1.96M 13.22M 5.19M 64.55M 5.15M 5.04M 222M	1.3M 1.49M 1.2M 1.1M 2.09M 143M 2.12M 14.32M 5.62M 69.93M 5.58M 5.46M 241M
Net income	-	-
Net Debt	-	-